Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study
Clicks: 199
ID: 116888
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
199 views
38 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #50 of 273 articles by views in the journal of clinical psychiatry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This study evaluated the efficacy and tolerability of escitalopram in adolescents with generalized anxiety disorder as well as the impact of variants in genes and CYP2C19 phenotypes on response and of CYP2C19 phenotypes on escitalopram pharmacokinetics.
| Reference Key |
strawn2020the
escitalopram
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jeffrey R. Strawn;Jeffrey A. Mills;Heidi Schroeder;Sarah A. Mossman;Sara T. Varney;Laura B. Ramsey;Ethan A. Poweleit;Zeruesenay Desta;Kim Cecil;Melissa P. DelBello; |
| Journal | the journal of clinical psychiatry |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.